@PledgeYou have attacked me (and so many others) on so many...

@Pledge

You have attacked me (and so many others) on so many occasions, yet you presume people want to listen to you?

You get being on social media, investor forums etc, you are expected to behave with the same decorum as normal society right? You can't walk into a room, punch someone in the stomach, and then expect to return again and be treated with the decorum. Nonetheless, I will indulge you.

Did I buy CYP at $2? No. Did I buy at $1? No. Did I buy at $0.50? No. Did I buy at $0.30? No. Is my buy average above this price? Of course, its practically on its lows, so almost logistically impossible for it not to be. Asides your obvious "no where is good to buy CYP" price, where exactly should I have bought CYP?

"Cash on hand" I will give you is a broad term, depending on context. Given this is finance, lets go with the generally accepted 'accessible money, funds in bank accounts, or liquid assets that could be accessed within less than 90 days'.

So CYP reported cash on hand at $13.5 million as of end of March in its Appendix 4C. Lets give you that officially:

"Financial position; Cynata closed the quarter with A$13.5m in cash, as at 31 March." (Its very naughty for ASX companies to lie about these things, so we can take that as true).

That was of course before it raised $5 million via Insto's and $2 million via retail. So after that it has $20.5 million cash on hand.

Now lets look at its last reported YTD cash burn, $10.5 over 9 months. Lets go heavier than that rate and presume its burned in less than two months, $2.5 million. So that would be $$18 million cash in hand Splodge.

So yeah, once again, you talk drivel in your acrimonious criticism and given CYP is trading at $23 million mkt cap, my statement that "CYP is nearly trading cash on hand value. That's absurd." is entirely valid.

Lets put this in an analogy, your mind (impaired with vitriolic thoughts of Sector and all those nasty CYP shareholders) can actually grasp. MSB reported cash on hand of $49 million at the end of March. It also raised cash recently, and had $89 million after that. Now I like MSB. A lot; so much so I own it, but it does go on about its undrawn debt facilities as if they are cash, so lets just stick to the $89 million cash. Now last YTD cash burn from MSB is about $16 million a quarter, so lets say assume it has burned $10 million.

So lets see, MSB has around $79 million cash on hand and a truck load of promising trials on hand with possible FDA, EMA and TGA approval not too far in the future, and trades for $900 million mkt cap. CYP has around $18 million in cash on hand and a truck load of promising trials on hand with possible FDA, EMA and TGA approval a little further in the future, but with arguably superior bio-tech, and trades for $23 million mkt cap. Are you grasping it yet?